Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.
Zacks.com on MSN1h
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes PatientsA late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients ...
The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.
The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...
WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing ...
Maselli's open letter comes on the back of criticism over Novo Holding's $16.5-billion acquisition of Catalent, which U.S.
For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for ...
President Biden and Sen. Bernie Sanders (I-Vt.) will travel to New Hampshire on Tuesday to speak on health care savings ...
Baron International Growth Fund increased in the third quarter of 2024, modestly outperforming its benchmark, the MSCI ACWI ...
WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing more benefits of these powerful medicines, it’s no wonder appetite ...
Zacks.com on MSN5h
5 Large Drug Stocks Likely to Outpace Q3 Earnings EstimatesLet us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback